12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IPI-145: Phase IIa started

Infinity began a double-blind, placebo-controlled, crossover Phase IIa trial to evaluate oral IPI-145 in about 30 patients with mild, allergic asthma undergoing allergen challenge. Last month, Mundipharma...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >